We can’t show the full text here under this license.
Abstract
A case of non-arteritic anterior ischemic optic neuropathy (NAION) occurred in a young patient with diabetes receiving semaglutide, a GLP-1 receptor agonist.
- Symptoms of NAION completely resolved after stopping semaglutide.
- Emerging evidence suggests a potential increase in NAION incidence among users of GLP-1 receptor agonists.
- Further studies are needed to clarify the relationship between GLP-1 RAs and NAION.
- Identifying risk factors and developing monitoring strategies for patients on GLP-1 RAs is essential.
Simplified